Drug intelligence / Profile preview

sabin-strain inactivated poliovirus vaccine + hepatitis A live attenuated vaccine

Development stage
Unknown
Lead developer
Sinovac Biotech
Modality
Vaccines & Immunotherapeutics
Administration
Intramuscular
01

Overview

This product is a **combination vaccine** containing **Sabin-strain inactivated poliovirus vaccine (sIPV)** and **hepatitis A live attenuated vaccine**. - **Sabin-strain inactivated poliovirus vaccine (sIPV):** An inactivated (killed virus) vaccine derived from the attenuated Sabin strains of poliovirus, developed to provide immunity against poliomyelitis without the risk of vaccine-associated paralytic poliomyelitis. sIPV works by stimulating the immune system to produce neutralizing antibodies (IgG) against poliovirus types 1, 2, and 3[1][2][4][5]. The Sabin strains, originally developed for oral vaccines, are used inactivated in this formulation, reducing biosafety risks and avoiding transmission through fecal shedding[5]. - **Hepatitis A live attenuated vaccine:** A vaccine containing live, weakened hepatitis A virus that stimulates cellular and humoral immunity for long-term protection against hepatitis A infection. The vaccine is primarily indicated for **protection against both poliomyelitis and hepatitis A**. It is used in populations where combined prevention is needed, such as pediatric immunization programs.

02

Targets

Hepatitis A virus capsid protein

Beyond the preview

Go deeper on sabin-strain inactivated poliovirus vaccine + hepatitis A live attenuated vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on sabin-strain inactivated poliovirus vaccine + hepatitis A live attenuated vaccine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call